Status:
TERMINATED
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
Lead Sponsor:
University of Padova
Conditions:
Cirrhosis
Ascites
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Nosocomial spontaneous bacterial peritonitis (SBP) is frequently caused by multi drug resistant bacteria. Standard treatment of SBP could be ineffective. The aim of the study is to compare daptomycin ...
Detailed Description
Spontaneous bacterial peritonitis (SBP) is a well known complication in patients with liver cirrhosis and ascites. Nosocomial SBP is defined as SBP that occurs after 48 hours of hospitalization. It ha...
Eligibility Criteria
Inclusion
- Patients with liver cirrhosis and ascites
- Meets all criteria for nosocomial SBP as outlined below
- Ascitic fluid polymorphonuclear cells count \>250/mm3
- Onset of signs and symptoms of infection after 72 hours of hospitalization
Exclusion
- Hepatocellular carcinoma beyond the Milan criteria
- Abdominal surgery within 4 weeks
- Evidence of secondary peritonitis, pancreatitis or peritoneal carcinomatosis
- Significant heart or respiratory failure
- Allergy to ceftazidime, meropenem or daptomycin
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01455246
Start Date
October 1 2010
End Date
July 1 2014
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Clinical and Experimental Medicine, University of Padova
Padua, PD, Italy, 35128